Navigation Links
Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
Date:5/7/2008

ption and win market share."

Volcano also said its product development programs remain on track, including the expected commercial launch in the second half of 2009 of its first image-guided therapy offering, a balloon and IVUS on the same catheter. Volcano also expects U.S. and European regulatory approval in the second half of 2009 for its initial Optical Coherence Tomography product incorporating the technology that the company acquired with its purchase of CardioSpectra at the end of 2007.

"Our new product initiatives are designed to offer a variety of modalities built around our s5i offering and to position Volcano to address a number of very sizeable therapy markets with innovative platform technologies," Huennekens noted. "We will also continue to explore strategic opportunities that provide offerings for our existing customer base and meet our growth rate, gross margin and valuation objectives," he added.

Guidance for 2008

The company updated its prior guidance for 2008. Volcano said it now expects revenues for the year will be in the range of approximately $164-$168 million. This compares with prior guidance of $158-$162 million, and represents an increase of approximately 26-29 percent over revenues in 2007. Gross margin is expected to be in the range of 60-61 percent, with the company expecting to exit 2008 with margins in the range of 63-64 percent. Operating expenses, including stock-based compensation, the $2.9 million in due diligence expense recorded in the first quarter, and approximately $3.1 million of intangible amortization, are expected to be 65-66 percent of revenues.

On a GAAP basis, the company expects to report a net loss of approximately $0.06-$0.10 per share. This compares to prior guidance for a net loss of $0.02-$0.04 per share. The decrease in guidance for earnings per share, despite the expected increase in revenues, reflects the due diligence expense, reduced interest income due to declining interes
'/>"/>

SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
2. Volcano Corporation Announces Pricing of Common Stock Offering
3. Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated
4. Volcano Announces Closing of CardioSpectra Acquisition
5. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
6. Volcano Announces FDA 510(k) Clearance of Revolution Rotational Catheter and FFR for the s5i Integrated IVUS Console
7. Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast
8. Volcano Announces U.S. and European Launch of Rotational IVUS and Integrated FFR
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... (PRWEB) March 04, 2015 PRC ... in the San Francisco Bay Area, will exhibit and ... Israel Conference 2015 on March 25th and 26th ... to build relationships with Israeli life science companies seeking ... trials. The company’s services span all phases of human ...
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... Dr. Gary Michelson,is "making an unprecedented investment on ... of Found Animals Foundation (Found,Animals) http://www.foundanimals.org, ... its strategic partner the Alliance for Contraception,in Cats ... Michelson Prize in,Reproductive Biology at the SPAY/USA Conference ...
... 20 Idenix,Pharmaceuticals, Inc., (Nasdaq: IDIX ) announced ... third quarter of 2008 on Thursday, October,30, 2008 after ... the issuance of the press release, Idenix,management will host ... October,30, 2008 to discuss the company,s financial results for ...
... Calif., Oct. 20 Amgen (Nasdaq:,AMGN) today announced that ... Wednesday, Oct. 22, 2008 after the close of the ... call with the,investment community at 1:30 p.m. Pacific Time. ... chairman and CEO, and other members of,Amgen,s senior management ...
Cached Biology Technology:Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4Amgen Announces Webcast of 2008 Third Quarter Financial Results 2
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... Using a new mathematical methodology, researchers at MIT have ... the physical structure of spider silk and the sonic structure ... to its function in an equivalent way. ... each item an amino acid and a sound wave ...
... imaging measures were associated with prognostic tumor markers, ... prediction of disease prognosis and stratification of patients ... at the 2011 CTRC-AACR San Antonio Breast Cancer ... are heterogeneous, and different subtypes of breast cancer ...
... 2011)The Academy of Natural Sciences of Drexel University has been ... of Museums. , AAM accreditation is a widely recognized seal ... meeting and often exceeding the standards and best practices of ... U.S., just 776, or 4.5 percent, hold AAM accreditation. , ...
Cached Biology News:Researchers link patterns seen in spider silk, melodies 2Researchers link patterns seen in spider silk, melodies 3MRI may be noninvasive method to measure breast cancer prognosis 2
... is available in a ready-to-use format. ... for dewaxing paraffin-embedded tissue sections prior ... or other analytical methods. The conventional ... dipping the slides in a series ...
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
For demonstration of Helicobacter pylori...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
Biology Products: